摘要
目的探究脑信号蛋白Sema4D及炎症因子在乙肝相关性肝癌患者中的表达及其意义。方法选取2017年1月-2018年12月我院肝病中心收治的41例乙肝相关性肝癌患者作为观察组,同期在我院体检的41例健康者作为对照组。检测并比较两组研究对象的脑信号蛋白Sema4D的表达水平,评估血清IL-8和IL-6水平的变化,同时探究Sema4D表达水平与炎症因子之间的相关性。结果观察组患者血清Sema4D、IL-8、IL-6水平均显著高于对照组(P<0.05);血清Sema4D水平与血清IL-8、IL-6水平呈正相关(r=0.935,P=0.002;r=0.912,P=0.016);单因素Logistic分析显示Sema4D表达水平升高是乙肝相关性肝癌发生的独立危险因素(OR=1.25,95%CI=1.04~1.87,P<0.001)。结论脑信号蛋白Sema4D可通过影响机体炎症反应水平,影响机体的神经内分泌功能及免疫系统功能,从而参与乙肝相关性肝癌的发生发展。
Objective To investigate the expression of brain signal protein Sema4D and levels of inflammatory factors,as well as their significance in patients with hepatitis B-related liver cancer.Methods Forty-one cases of Hepatitis B-related liver cancer patients who were admitted to the First Hospital of Hunan University of Chinese Medicine between January 2017 and December 2018 were selected as observation group.Forty-one healthy people who got health examination during the same period were selected as the control group.The expression levels of Sema4D in the two groups were detected and compared,and the changes of serum IL-8 and IL-6 levels were evaluated.Correlations between Sema4D expression levels and inflammatory factors were also analyzed.Results The serum levels of Sema4D,IL-8 and IL-6 in the observation group were higher than those of the control group(P<0.05).In addition,the expression level of Sema4D were positively correlated with the levels of IL-8 and IL-6(r=0.935,P=0.002;r=0.912,P=0.016).Moreover,single factor logistic analysis showed that the elevated level of Sema4D was independent risk factor for hepatitis B-related liver cancer(OR=1.25,95%CI=1.04~1.87,P<0.001).Conclusion Brain signal protein Sema4D may affect the development and progression of hepatitis B-related liver cancer by regulating the level of body inflammatory response and affecting the neuroendocrine function and immune system function of the body.
作者
王若宇
伍玉南
唐丹
WANG Ruoyu;WU Yunan;TANG Dan(The First Hospital of Hunan University of Chinese Medicine,Changsha,Hunan,410000,China)
出处
《肿瘤药学》
CAS
2019年第6期875-878,共4页
Anti-Tumor Pharmacy
基金
湖南省自然科学基金(2019JJ50469)